Interpreting the 39% clinical complete response rate in SURE-02: why the assessment pathway matters
Shugo Yajima, Hitoshi Masuda · 2026
Read Interpreting the 39% clinical complete response rate in SURE-02: why the assessment pathway matters by Shugo Yajima, Hitoshi Masuda (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13657766.txt.
Description
Shugo Yajima and Hitoshi Masuda comment on a bladder cancer trial's headline result, in this 2026 piece. The SURE-02 trial gave a drug pair before surgery to patients unfit for standard chemotherapy, and reported that thirty-nine percent reached a full clinical response. The commentators stress that the number describes a treatment-and-assessment path, not the drugs alone.
Only patients who chose repeat bladder sampling after treatment could be scored as full responders, and all nineteen responses sat in that group. Counted within that group alone, the share is higher but reflects who was picked, not a second effect. The piece urges care in reading such rates.
Catalog record
| CREATOR | Shugo Yajima, Hitoshi Masuda |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |